SAP partners with OpenAI and Microsoft to deliver sovereign cloud-based AI for German public sector

Christian Klein Chief Executive Officer (CEO) SAP SE
Christian Klein Chief Executive Officer (CEO) - SAP SE
0Comments

SAP SE and OpenAI have announced a partnership to launch OpenAI for Germany, aiming to bring artificial intelligence solutions tailored for the German public sector. The initiative will use SAP’s subsidiary Delos Cloud, which operates on Microsoft Azure technology, to ensure data sovereignty and compliance with German security and legal requirements.

Christian Klein, CEO of SAP SE, stated, “Applied AI is what truly creates value. As a Business AI company with decades of experience serving public sector organizations, we believe OpenAI for Germany represents a huge step forward. We’re bringing together SAP Sovereign Cloud expertise with OpenAI’s leading AI technology to pave the way for AI solutions that are built in Germany, for Germany.”

Sam Altman, CEO of OpenAI, added, “Germany has long been a pioneer in engineering and technology, so it’s no surprise that millions of Germans already use ChatGPT to make their lives easier, drive scientific breakthroughs, and build new businesses. With OpenAI for Germany, we’ll work with local partners to extend this potential to the public sector—helping to improve services and ensuring that the benefits of AI are shared across the country, and doing so in line with German values of trust and safety.”

Satya Nadella, Chairman and CEO of Microsoft, commented on the collaboration: “With this partnership we are looking forward to bringing more AI capabilities to Germany’s public sector. Azure as the platform for Delos Cloud will power this, helping to ensure AI is deployed with the highest standards of sovereignty, data privacy, regulatory compliance, and operational resilience—empowering public institutions to adopt AI confidently and responsibly.”

The project is scheduled for launch in 2026. The three companies plan to focus on enabling employees in government bodies and research institutions across Germany to utilize AI tools effectively in daily tasks. The partnership aims at developing customized applications for the public sector as well as integrating artificial intelligence agents into existing workflows. This includes automating processes such as records management and administrative data analysis.

To support these objectives, SAP intends to expand Delos Cloud’s infrastructure within Germany by increasing its capacity to 4,000 GPUs dedicated for AI workloads. The company also plans additional investments based on future demand through both internal infrastructure expansion and partnerships with co-location providers.

This initiative aligns closely with national strategies such as Germany’s High-Tech Agenda that seeks up to 10% GDP growth from AI-driven innovation by 2030. Additionally, it complements the “Made for Germany” campaign—which now includes support from 61 major companies including SAP—that has pledged over €631 billion towards economic modernization through digital technologies. Recently SAP itself committed more than €20 billion towards enhancing digital sovereignty within Germany.

Further details about this announcement can be found via the SAP News Center.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.